Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Asparaginase Erwinia chrysanthemi |
| Synonyms | |
| Therapy Description |
Erwinaze (asparaginase Erwinia chrysanthemi) is an bacterial derived enzyme that converts L-asparagine to L-aspartate and ammonia, which decreases L-asparagine levels, potentially leading to reduced leukemic cell growth (PMID: 25098829, PMID: 26698391). Erwinaze (asparaginase Erwinia chrysanthemi) is FDA-approved for use in a chemotherapeutic regimen for acute lymphoblastic leukemia (FDA.gov). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Asparaginase Erwinia chrysanthemi | Erwinaze | Crisantaspase|JZP458|JZP-458|JZP 458|Rylaze|PF743|RC-P JZP-458 | Erwinaze (asparaginase Erwinia chrysanthemi) is an bacterial derived enzyme that converts L-asparagine to L-aspartate and ammonia, which decreases L-asparagine levels, potentially leading to reduced leukemic cell growth (PMID: 25098829, PMID: 26698391). Erwinaze (asparaginase Erwinia chrysanthemi) is FDA-approved for use in a chemotherapeutic regimen for acute lymphoblastic leukemia (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|